

Consensus recommendations for the diagnosis and management of hemophagocytic lymphohistiocytosis associated with malignancies

Kai Lehmborg,¹ Kim E. Nichols,² Jan-Inge Henter,³ Michael Girschikofsky,⁴ Tatiana Greenwood,³ Michael Jordan,⁵ Ashish Kumar,⁵ Milen Minkov,⁶ Paul La Rosée,⁷ and Sheila Weitzman,⁸ for the Study Group on Hemophagocytic Lymphohistiocytosis Subtypes of the Histiocyte Society

¹Department of Pediatric Hematology and Oncology, University Medical Center Eppendorf, Hamburg, Germany; ²Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA; ³Childhood Cancer Research Unit, Department of Women's and Children's Health, Karolinska Institutet, Karolinska University Hospital Solna, Stockholm, Sweden; ⁴Department of Medicine I, Hematology and Stem Cell Transplantation, Hemostasis and Medical Oncology, Elisabethinen Hospital, Linz, Austria; ⁵Department of Immunology, Cincinnati Children's Hospital, OH, USA; ⁶Department of Pediatric Hematology and Oncology, St. Anna Children's Hospital, Vienna, Austria; ⁷Klinik für Innere Medizin II, Abt. Hämatologie und internistische Onkologie, Universitätsklinikum Jena, Germany; and ⁸Department of Hematology and Oncology, Sick Kids Hospital, Toronto, Canada

ABSTRACT

The hyperinflammatory syndrome hemophagocytic lymphohistiocytosis can occur in the context of malignancies. Malignancy-triggered hemophagocytic lymphohistiocytosis should be regarded separately from hemophagocytic lymphohistiocytosis during chemotherapeutic treatment, which is frequently associated with an infectious trigger. The substantial overlap between the features of hemophagocytic lymphohistiocytosis with features of neoplasms makes its identification difficult when it occurs in malignant conditions. To facilitate recognition and diagnostic workup, and provide guidance regarding the treatment of malignancy-associated hemophagocytic lymphohistiocytosis, consensus recommendations were developed by the Study Group on Hemophagocytic Lymphohistiocytosis Subtypes of the Histiocyte Society, an interdisciplinary group consisting of pediatric and adult hemato-oncologists and immunologists.

Introduction

Hemophagocytic lymphohistiocytosis (HLH) represents a spectrum of hyperinflammatory disorders associated with activation of cytotoxic T and natural killer (NK) cells, and macrophages. The excessive immune activation results in the clinical hallmarks of HLH, including fever, hepatosplenomegaly and cytopenias, combined with a characteristic set of laboratory parameters (elevated ferritin, triglycerides, soluble CD25, transaminases, lactate dehydrogenase, d-dimers; decreased fibrinogen, albumin, sodium). Hereditary or "primary" HLH is comprised of several genetically heterogeneous conditions, including familial HLH 2-5, Griscelli syndrome type II, and the X-linked lymphoproliferative syndromes, among others. Primary HLH predominantly occurs during childhood and may be triggered by an infection. As is the case with primary HLH, acquired or secondary HLH is not a stand-alone disease entity. Rather, secondary HLH represents a group of disorders that can occur under a variety of circumstances. The most frequent triggers are infection, in particular with viruses such as Epstein-Barr virus (EBV) and cytomegalovirus (CMV). However, the disease can also be induced by certain malignancies, and autoimmune or autoinflammatory conditions. Due to their rarity, and the heterogeneity of inciting factors and clinical outcomes, the diagnosis and management of secondary forms of HLH has remained challenging. The substantial overlap between the features of HLH and features of neoplasms makes the identification of HLH when it occurs in the context of a malignancy very difficult. To facilitate recognition and diagnostic workup and provide guidance regarding the treatment of malignancy-

associated HLH, the following consensus recommendations were created. These recommendations will not address HLH that occurs after hematopoietic stem cell transplantation.

Methods

The recommendations were developed by the Study Group on HLH Subtypes of the Histiocyte Society, an interdisciplinary group consisting of pediatric and adult hemato-oncologists and immunologists. Initially, the pertinent literature in Pubmed was reviewed. No randomized clinical trials, case control or cohort studies could be identified, which restricts the level of evidence to non-analytic studies and case series (level of evidence 4, based on the Oxford Centre for Evidence-Based medicine; <http://www.cebm.net/oxford-centre-evidence-based-medicine-levels-evidence-march-2009>) or expert opinion (level of evidence 5). Subsequently, core statements were developed, critically revised and modified by the Study Group to achieve the highest possible agreement, which was classified as "full consensus" (100%) or "consensus" ($\geq 80\%$). None of the core statements achieved a degree of consensus below 80%. The level of evidence and degree of consensus is specified in this document. Finally, the recommendations were written along with the core statements and reviewed by all authors.

General information

Core Statement 1 (level of evidence 5, full consensus): HLH can occur either as the initial manifestation of malignant disease (here referred to as "Malignancy-

Triggered HLH⁴⁾ or in the setting of iatrogenic immunosuppression from chemotherapy (“HLH During Chemotherapy⁴⁾).

Hemophagocytic lymphohistiocytosis can occur in the context of a neoplasm under two different scenarios. First, it may be a presenting feature of the disease at onset or at relapse (“Malignancy-Triggered HLH⁴⁾). Second, it can occur during, or shortly after, chemotherapeutic treatment for a malignancy (“HLH During Chemotherapy⁴⁾) while patients frequently are in remission from the malignancy. It is not completely understood why Malignancy-Triggered HLH occurs. Data generated using lymphoma cell lines suggest that secretion of cytokines (including interferon- γ and interleukin-6) by the malignant cells contributes to the development of hyperinflammation.^{1,2} Elevated soluble CD25 is considered a marker of T-cell activity in HLH, as well as a marker that correlates with tumor burden in non-Hodgkin lymphoma.^{3,4} In patients with Malignancy-Triggered HLH, viral infections may act as co-triggers. This is exemplified by EBV-associated lymphomas,⁵ where both the virus and the lymphoma can drive HLH.

HLH During Chemotherapy, in the majority of cases, develops in association with triggering infections that occur as the result of chemotherapy-induced immunosuppression. The first connection of iatrogenic immunosuppression with consecutive infection and HLH was shown in a series of patients receiving immunosuppressive treatment after kidney transplantation.⁶ In contrast to infection-associated HLH in non-immunocompromised patients, where viruses are the major inciting pathogens, invasive fungi and bacterial infections may also play a substantial role in HLH During Chemotherapy.⁷⁻¹⁰

It is often difficult to differentiate between Malignancy-Triggered HLH and HLH During Chemotherapy, and these conditions may co-exist, such as in a patient with reactivation of a malignancy that also has an infection. In such situations, both the malignancy and the infection may contribute to the HLH.

Core Statement 2 (level of evidence 4, full consensus): Malignancy-Triggered HLH occurs most frequently but not exclusively with:

- T-cell and NK-cell lymphomas or leukemias
- diffuse large B-cell lymphoma (DLBCL)
- Hodgkin lymphoma.

The proportion of each tumor type in adult patients with HLH in the context of a neoplasm is reported to be 35% for T-cell or natural-killer (NK) lymphomas, 32% for B-cell lymphomas, 6% for leukemias, 6% for Hodgkin lymphomas, 14% for other and non-specified hematologic neoplasms, 3% for solid tumors, and 3% for not specified neoplasms.¹¹ Large series suggest that, in adults, DLBCL is the predominant trigger in Western countries and Japan,^{12,13} while T-cell neoplasms are the major cause in China and Korea.¹⁴⁻¹⁶ In children, T-cell malignancies predominate.^{17,18} T-cell cancers that are more likely to trigger HLH include peripheral T-cell lymphomas (particularly subcutaneous panniculitis-like T-cell lymphoma), primary cutaneous $\gamma\delta$ -T-cell lymphoma,^{19,20} anaplastic large cell lymphoma and, less commonly, lymphoblastic lymphomas.¹⁷

Diffuse large B-cell lymphoma is the most frequent neo-

Table 1. Diagnostic criteria.

HLH-2004 diagnostic criteria	
Feature	Cut off
1. Fever	
2. Splenomegaly	
3. Cytopenia	≥ 2 cell lines
Hemoglobin	< 90 g/L (neonates <100 g/L)
Platelets	<100x10 ⁹ /L
Neutrophils	<1x10 ⁹ /L
4. Hyperferritinemia	>500 μ g/L
5. Hypofibrinogenemia	< 1.5 g/L
or hypertriglyceridemia	> 3 mmol/L
6. Elevated soluble CD25	> 2400 U/mL
7. Hemophagocytosis	Bone marrow, other tissues
8. Reduced or absent NK cytotoxicity	
Other features	
Elevated transaminases and bilirubin	
Elevated lactate dehydrogenase	
Elevated d-dimers	
Elevated cerebrospinal fluid cells and/or protein	

NK: natural killer cells.

plasm of B-cell origin that triggers HLH, especially in patients over 60 years of age. In Far East Asia, intravascular large B-cell lymphoma appears to have a special propensity to elicit HLH.²¹ B-precursor neoplasms are not frequently reported.¹⁰ In Hodgkin lymphoma, the occurrence of HLH is not confined to a specific subtype.^{22,23} The prevalence of EBV as a co-trigger varies between up to 90% in Hodgkin lymphoma^{5,24} to approximately 33% in peripheral T-cell lymphoma,^{12,15} while it is low in DLBCL.^{25,26}

Other malignant or non-malignant hematologic conditions that have been associated with HLH include EBV-associated T/NK-cell lymphoproliferative diseases predominantly found in Far East Asia,^{27,28} Langerhans cell histiocytosis,⁷ multicentric Castleman disease in HIV patients,²⁹ and cytophagic histiocytic panniculitis.³⁰

Solid tumors are not commonly associated with HLH with only a 3% prevalence in adults.¹¹ In particular, mediastinal germ-cell tumors have been reported.³¹ Interestingly, secondary malignant neoplasms (particularly acute myeloid leukemia) have been reported in patients after treatment of HLH, most likely attributable to high cumulative doses of the topoisomerase inhibitor etoposide; however, no recurrence of HLH has been reported in this context.³²

Core Statement 3 (level of evidence 4, full consensus): HLH during chemotherapy is most frequently found during leukemia and lymphoma treatment, and during any phase of the therapy. It is frequently associated with an infectious trigger, including viruses, bacteria, and fungi.

In adult and pediatric oncology, aggressive therapies for malignant hematologic neoplasms carry the highest risk of developing secondary HLH. This is not restricted to induc-

tion and consolidation therapy but also occurs during maintenance.⁸ The prevalence of an infectious trigger ranges from 75% to 100%.^{7-10,33} Inflammatory toxicities thought to be due to pro-inflammatory cytokine release after administration of chimeric antigen receptor (CAR)-modified T cells and bispecific T-cell-engaging (BiTE) antibodies for the treatment of B-precursor leukemias appear very similar to HLH, and may share some aspects of pathophysiology with HLH, as seen in more typical contexts.⁵⁴

Core Statement 4 (level of evidence 4, full consensus): In a patient with HLH, the likelihood of an underlying malignant disease increases with age.

In adults, nearly half of the published cases were triggered by a neoplasm¹¹ and approximately 1% of adult patients with a hematologic malignancy develop HLH.³⁵ A large Japanese survey of 799 HLH patients evaluated the correlation between age and lymphoma as trigger. A lymphoma was found in 68% of patients aged over 60 years, in 38% aged 30-59, in 10% aged 15-29, and in 0% under 14 years of age.¹² In children and adolescents, a malignant context in HLH has a reported prevalence of 8%.¹⁸

Diagnostics

Here we consider 2 distinct clinical scenarios (Figure 1). First, an underlying malignancy must be excluded or confirmed in a patient with proven HLH. Second, HLH is suspected in a patient diagnosed with a malignant condition, initially or during treatment.

Core Statement 5 (level of evidence 5, full consensus): Currently, there are no generally accepted criteria for the definition of Malignancy-Triggered HLH or HLH During Chemotherapy. The HLH-2004 criteria may serve as a substitute definition, but they have substantial weaknesses.

The diagnosis of HLH is based on a set of clinical features and laboratory parameters. The first set of criteria was defined in the 1990s for pediatric patients of the international treatment HLH-94 study. It was later adapted for the subsequent HLH-2004 study.³⁶ The parameters that should be determined when HLH is suspected are listed in Table 1. In the context of malignancy, several of these characteristics may be present and caused by the HLH and/or by the neoplasm (e.g. fever, organomegaly, cytopenias, elevated lactate dehydrogenase, and coagulation disturbances). Furthermore, elevation of ferritin must be differentiated from transfusion-related iron overload. Despite the term hemophagocytic lymphohistiocytosis, hemophagocytosis in the bone marrow, lymph nodes, or liver is neither a sensitive nor a specific finding in HLH,³⁷ and it may be present in several conditions related with malignancies, such as septicemia.

For clinical purposes, it is thus crucial to judge whether:

1. the combination
2. the extent, and
3. the progression of the mentioned clinical and laboratory abnormalities are unusual, unexpected, and otherwise unexplained.

For the purposes of definition and scientific classification of HLH, the HLH-2004 diagnostic criteria constitute

the most widely used tool in pediatric and adult oncology. However, it must be noted that the development of these criteria was based on small pediatric data sets and expert opinion. Modifications have been suggested.^{38,39} Takahashi et al. proposed diagnostic criteria for adult lymphoma-associated hemophagocytic syndrome on the basis of 142 cases, which have so far not gained wide acceptance. They include most of the HLH-2004 criteria, but in a slightly different composition, along with lactate dehydrogenase and d-dimers.^{25,40} Importantly, the presence of an infection should not be regarded as contradictory to a malignant trigger. A scoring system was designed by Fardet *et al.*, based on a study with 312 adult patients with and without HLH and a 45% prevalence of hematologic malignancies.⁴¹ The score is based on weighted features similar to the HLH-2004 criteria, intended to predict the likelihood of presence of HLH.

Temperature, spleen size, blood count, ferritin, fibrinogen, soluble CD25, and LDH can be used as markers of disease activity and treatment response. Platelets tend to rapidly reflect the level of HLH activity, with a drop in the platelet count indicating flares of disease. Ferritin rapidly increases in active HLH; however, levels normalize rather slowly following resolution of inflammation.⁴² Here again, differentiation between the effects of the underlying neoplasm and HLH can be difficult. A repeat bone marrow aspirate may be indicated if cytopenias persist to determine whether they are related to treatment toxicity or active HLH.

Core Statement 6 (level of evidence 4, full consensus): In any patient with HLH, malignancy should be considered as a possible underlying disease.

An unidentified neoplasm can be the triggering factor in any patient with HLH, the most common being occult lymphomas. However, several factors modify this likelihood. While it is exceptionally rare in infancy, malignancy is the most frequent trigger in the elderly (*see Core Statement 4*). The diagnosis of another plausible trigger of HLH reduces the probability, but never excludes it. This also applies to the finding of pertinent infectious agents (e.g. EBV, CMV, Leishmaniasis). EBV is the most frequent trigger of acquired infection-associated HLH, and it is also frequently present in Malignancy-Associated HLH (e.g. in EBV-driven lymphomas).⁵ In more than half of adult patients with HIV and HLH, an underlying malignancy, usually a lymphoma, can be found.⁴³ Autoimmune (e.g. systemic lupus erythematosus) and autoinflammatory diseases (e.g. systemic juvenile idiopathic arthritis, adult onset Still's Disease) may underlie HLH, with variable clinical overlap to malignancies, such as fever and cytopenias. A considerable diagnostic uncertainty with these diseases is quite common. In a patient with HLH and a rheumatological diagnosis, it is recommended to carefully search for a malignancy so any hidden neoplasm is not missed. The presence of a hereditary condition predisposing to HLH renders malignancy less likely, but does not exclude it (*compare Core Statement 8*).

Core Statement 7 (level of evidence 5, consensus): The required extent of diagnostic work up aimed at excluding a malignant condition (in particular an occult lymphoma) depends upon the likelihood that a malignancy might be present.




Figure 1. Flow chart for diagnosis and management of malignancy-associated hemophagocytic lymphohistiocytosis.

In all patients with HLH, the peripheral blood and the bone marrow should be screened for blasts. A chest X-ray, ultrasound and/or computed tomography of the abdomen and enlarged lymph nodes are recommended. Suspicious lymph nodes or cutaneous lesions indicative of lymphoma should be biopsied. In patients with elevated likelihood of malignancy (*compare Core Statement 6*), computed tomography, magnetic resonance imaging (MRI), and, in special cases, positron emission tomography⁴⁴ may be taken into consideration. Cerebrospinal fluid⁴⁵ should be screened for features of central nervous system involvement of HLH (elevation of protein and cell count, hemophagocytosis) and an MRI⁴⁶ of the brain should be strongly considered in patients with neurological signs and symptoms or in those with elevated protein and/or CSF cell count.

Core Statement 8 (level of evidence 4, full consensus): Malignancy-Triggered HLH has been described in patients with hereditary HLH and other primary immunodeficiencies. This association is most prominent in X-linked lymphoproliferative syndrome (XLP).

Several hereditary defects predispose to primary HLH (familial HLH type 2-5, Griscelli syndrome type 2, Chediak-Higashi syndrome, X-linked lymphoproliferative syndromes type 1 and 2, and others).³⁸ The age at onset of primary HLH is mostly in childhood. Nonetheless, it has been increasingly identified in adolescents and adults.⁴⁷ The decision as to whether a hereditary defect predisposing to HLH should be excluded in a patient with HLH in the context of malignancy should be taken on a case-by-case basis. This can be done by flow cytometric analysis as a measure to detect NK/T-cell degranulation defects and/or to determine the expression of relevant proteins [perforin, SAP (XLP1)]. Functional deficits should trigger HLH genetic testing to determine the exact genetic lesion.⁴⁸ Furthermore, an association with EBV susceptibility and lymphoma has been described for deficiency of magnesium transporter 1 (MAGT1), Interleukin-2-inducible T-cell kinase (ITK), and CD27. Patients with these disorders can display features resembling HLH. X-linked lymphoproliferative syndrome 1 (XLP1) is characterized by the triad of development of HLH most commonly at primary infection with EBV, hypogammaglobulinemia, and lymphoma. These manifestations can occur together or in isolation. In a retrospective analysis of 91 patients diagnosed with XLP1, 24% had had a malignant lymphoproliferative disorder, usually B-lineage non-Hodgkin lymphoma.⁴⁹ In male patients with lymphoma and EBV-driven HLH, genetic or flow cytometric analysis for XLP1⁵⁰ should thus be strongly considered. There is no evidence that XLP2 predisposes to malignancy.

In rare cases of HLH in the context of malignancy, mutations in HLH-associated genes can contribute to the development not only of the HLH, but also of the malignancy. For example, mice lacking perforin, the gene mutated in FHL2, are more susceptible to lymphoma.⁵¹ Hypomorphic biallelic perforin mutations confer predisposition to late-onset HLH as well as hematologic malignancies.^{52,53} The presence of the perforin variant A91V with a high allele frequency in the Caucasian population (4%-17% heterozygous carriers)^{54,56} was initially reported to be more prevalent in 100 pediatric patients with acute lymphoblastic leukemia (ALL).⁵⁶ A large study of 2272 children with

ALL could not corroborate this finding in the general population of childhood ALL but supported it in a small subset of patients with BCR-ABL positive ALL.⁵⁵ Solid tumors (e.g. colorectal cancer and ovarian carcinoma) do not appear to be associated with perforin mutations.⁵⁷ Hodgkin lymphoma has been described in individuals with various genetic forms of HLH.⁵⁸⁻⁶¹

Treatment

Core Statement 9 (level of evidence 5, consensus): in Malignancy-Triggered HLH:

- it is uncertain whether primarily a malignancy-directed or an HLH-directed regimen should be used. This must be decided case by case;
- infectious triggers require rigorous treatment. Anti-infectious prophylaxis (anti-fungal, *pneumocystis jiroveci*) and regular surveillance for secondary infections or reactivations (fungi, EBV, CMV) should be strongly considered in active HLH;
- anti-B-cell therapy (e.g. rituximab) may be considered in cases marked by highly replicative EBV infection.

The mainstays of treatment of primary and infection-associated secondary HLH are immunoglobulins, glucocorticosteroids, cyclosporin A, and etoposide (VP16). A combination of the latter three has been used in the HLH-94 and HLH-2004 protocols.⁵⁶ Anti-thymocyte globulin (ATG) has shown efficacy in a cohort of mainly primary HLH patients⁶² and alemtuzumab (anti-CD52) has been shown beneficial as a salvage agent in a limited number of patients.⁶³ Anti-interleukin-1 treatment can be used for HLH in auto-inflammatory conditions, in addition to glucocorticosteroids, cyclosporin A, and etoposide.⁶⁴

The treatment of Malignancy-Associated HLH has not been prospectively studied. Due to the heterogeneity of patients and therapies in the published series,^{14,16,65} no clear conclusions can be drawn as to whether an HLH-directed, malignancy-directed, or combined approach should initially be adopted. If an HLH-directed therapy is chosen, it must be followed by a neoplasm-directed protocol when the HLH resolves. A study of 162 adult patients with secondary HLH reported better survival after use of etoposide (in comparison to treatment directed at the underlying pathology or treatment with glucocorticosteroids only). However, due to the retrospective nature of the study, patients were not randomized and no separate analysis of the Malignancy-Triggered HLH subgroup (52%) was performed.⁶⁶

In the murine model of familial HLH type 2 (perforin deficiency), mice with acute HLH receiving doxorubicin, clofarabine, cladribine, vinblastin, fludarabine, or L-asparaginase did not survive, while mice receiving etoposide, cyclophosphamide, or methotrexate did.⁶⁷ It is thus possible that lymphoma regimens containing the latter three agents treat both the HLH and the underlying neoplasm. Among these, etoposide is the substance for which clinical experience is greatest.^{36,66} The frequently-used lymphoma regimen CHOP contains cyclophosphamide, doxorubicin, vincristine, and prednisolone; in other protocols etoposide (e.g. CHOEP) or methotrexate is added.

Occasional reports indicate that cyclosporin A shows efficacy in clonal cytophagic histiocytic panniculitis and

even subcutaneous panniculitis-like T-cell lymphoma with features of HLH.^{30,63} It has been suggested that cytokine release syndrome after T-cell engaging therapies can be treated with interleukin-6 blockade by tocilizumab, while the use of corticosteroids might result in a lower anti-malignancy effect of chimeric antigen receptor T cells.^{34,69} However, due to the different pathogenesis of this iatrogenic condition, it is not clear whether tocilizumab will be effective as a treatment for HLH when it occurs in the context of malignancy.

Anti-viral treatment should be instituted if a treatable viral trigger is found, such as CMV or adenovirus. A beneficial impact of rituximab has been reported for some patients with EBV-driven HLH without malignancy.⁷⁰ Anti-B-cell treatment may thus be considered for HLH in the context of malignancy with EBV as a co-trigger. An additional neoplasm-directed effect may be assumed in cases of CD20-positive lymphomas. In addition to initial triggering infections, secondary infections frequently occur due to disease- and treatment-related immunosuppression. Anti-infectious prophylaxis (anti-fungal, *pneumocystis jiroveci*) and screening surveillance (aspergillus, EBV and CMV) should thus be strongly considered.

When comparing outcome data, death by HLH and death by the cancer should be ideally regarded separately. However, it is frequently impossible to differentiate between these two. The following estimators of survival have been reported for adults: a 30-day survival of the acute phase of Malignancy-Associated HLH of approximately 56%-70%, a median overall survival of 36-230 days, and a 3-year survival of 18%-55% (depending on the subtype). HLH triggered by a T-cell lymphoma has a worse prognosis than HLH occurring in the setting of a B-cell lymphoma. In a patient with lymphoma, the presence of HLH is prognostic of a poorer survival and early death.^{12,15,16,65,66,71,72} It has thus been suggested that stem cell transplantation might be considered as consolidation in patients with HLH in the context of a hematologic malignancy. For pediatric patients, 56% survival following the acute phase of HLH and 36% at five years have been reported.¹⁷

Core Statement 10 (level of evidence 5, full consensus): In HLH During Chemotherapy:

- **postponing subsequent chemotherapeutic blocks or interruption of maintenance therapy should be strongly considered, except for the event of relapse of the neoplasm;**

- **the necessity and extent of HLH-directed treatment depends on the clinical severity;**

- **infectious triggers require rigorous treatment. Anti-infectious prophylaxis (anti-fungal, *pneumocystis jiroveci*) and regular surveillance for secondary infections or reactivations (aspergillus,**

EBV and CMV) should be strongly considered in active HLH;

- **anti-B-cell therapy may be considered in highly replicative EBV infection.**

Only very limited data on the treatment of HLH During Chemotherapy are available. Since an infectious trigger is very frequent in this group, anti-infectious treatment plays a pivotal role (see previous section, including rituximab for EBV). Anti-infectious prophylaxis (anti-fungal, *pneumocystis jiroveci*) and screening surveillance (*aspergillus*, EBV and CMV) should be strongly considered. Patients with HLH During Chemotherapy are usually profoundly cytopenic and immunosuppressed. A potential positive effect of additional immunosuppression on HLH symptoms must be weighed against a possible negative effect on the treatment of the infection. Consequently, the extent and duration of HLH-directed therapy thus depends on the severity of HLH and the underlying trigger. At the lower end of intensity, consecutive blocks of chemotherapy are merely postponed or maintenance therapy is interrupted. In addition, glucocorticosteroids and immunoglobulins have been administered to children and adults.^{9,33,73} Whether the administration of more aggressive treatment such as etoposide is beneficial or counterproductive in this situation remains a subject of controversy.^{9,35}

With regard to prognosis, adult patients with features of HLH during treatment for AML had a median overall survival of 15 months, which was significantly lower than in patients without HLH features.⁹

Summary and Conclusions

Malignancies and infections during chemotherapeutic immunosuppression are major triggering events of HLH. The tools currently being used to diagnose HLH when it occurs in the context of a malignancy are far from perfect, as the neoplasm and treatment-induced toxicities complicate interpretation of laboratory and clinical parameters. Nevertheless, heightened clinical awareness and use of the criteria available can facilitate HLH diagnosis and thus direct subsequent therapy. Given the lack of robust evidence on the optimal choice of therapeutic interventions, treatment decisions must currently be made on a case-by-case basis. It is anticipated that future prospective investigations of adults and children with Malignancy-Triggered HLH or HLH During Chemotherapy will increase understanding of the clinical and biological bases of these poorly understood, and often life-threatening, disorders.

Authorship and Disclosures

Information on authorship, contributions, and financial & other disclosures was provided by the authors and is available with the online version of this article at www.haematologica.

References

1. Al-Hashmi I, Decoteau J, Gruss HJ, et al. Establishment of a cytokine-producing anaplastic large-cell lymphoma cell line containing the t(2;5) translocation: potential role of cytokines in clinical manifestations. *Leuk Lymphoma*. 2001;40(5-6):599-611.
2. Siebert S, Amos N, Williams BD, Lawson TM. Cytokine production by hepatic anaplastic large-cell lymphoma presenting as a rheumatic syndrome. *Semin Arthritis Rheum*. 2007;37(1):63-67.
3. Perez-Encinas M, Villamayor M, Campos A, Gonzalez S, Bello JL. Tumor burden and serum level of soluble CD25, CD8, CD23, CD54 and CD44 in non-Hodgkin's lymphoma. *Haematologica*. 1998;83(8):752-754.
4. Janik JE, Morris JC, Pittaluga S, et al. Elevated serum-soluble interleukin-2 receptor levels in patients with anaplastic large cell lymphoma. *Blood*. 2004;104(10):3355-3357.
5. Menard F, Besson C, Rince P, et al. Hodgkin lymphoma-associated hemophagocytic syndrome: a disorder strongly correlated with Epstein-Barr virus. *Clin Infect Dis*. 2008;47(4):531-534.
6. Risdall RJ, McKenna RW, Nesbit ME, et al. Virus-associated hemophagocytic syn-

- drome: a benign histiocytic proliferation distinct from malignant histiocytosis. *Cancer*. 1979;44(3):993-1002.
7. Celkan T, Berrak S, Kazanci E, et al. Malignancy-associated hemophagocytic lymphohistiocytosis in pediatric cases: a multicenter study from Turkey. *Turk J Pediatr*. 2009;51(3):207-213.
 8. Trebo MM, Attarbaschi A, Mann G, Minkov M, Kornmuller R, Gadner H. Histiocytosis following T-acute lymphoblastic leukemia: a BFM study. *Leuk Lymphoma*. 2005;46(12):1735-1741.
 9. Delavigne K, Berard E, Bertoli S, et al. Hemophagocytic syndrome in patients with acute myeloid leukemia undergoing intensive chemotherapy. *Haematologica*. 2014;99(3):474-480.
 10. Kelly C, Salvi S, McClain K, Hayani A. Hemophagocytic lymphohistiocytosis associated with precursor B acute lymphoblastic leukemia. *Pediatr Blood Cancer*. 2011;56(4):658-660.
 11. Ramos-Casals M, Brito-Zeron P, Lopez-Guillermo A, Khamashta MA, Bosch X. Adult haemophagocytic syndrome. *Lancet*. 2014;383(9927):1503-1516.
 12. Ishii E, Ohga S, Imashuku S, et al. Nationwide survey of hemophagocytic lymphohistiocytosis in Japan. *Int J Hematol*. 2007;86(1):58-65.
 13. Riviere S, Galicier L, Coppo P, et al. Reactive hemophagocytic syndrome in adults: A multicenter retrospective analysis of 162 patients. *Am J Med*. 2014; 127(11):1118-25.
 14. Li J, Wang Q, Zheng W, et al. Hemophagocytic lymphohistiocytosis: clinical analysis of 103 adult patients. *Medicine (Baltimore)*. 2014;93(2):100-105.
 15. Yu JT, Wang CY, Yang Y, et al. Lymphoma-associated hemophagocytic lymphohistiocytosis: experience in adults from a single institution. *Ann Hematol*. 2013; 92(11):1529-1536.
 16. Han AR, Lee HR, Park BB, et al. Lymphoma-associated hemophagocytic syndrome: clinical features and treatment outcome. *Ann Hematol*. 2007;86(7):493-498.
 17. Veerakul G, Sanpakit K, Tanphaichitr VS, Mahasandana C, Jirattanasopa N. Secondary hemophagocytic lymphohistiocytosis in children: an analysis of etiology and outcome. *J Med Assoc Thai*. 2002;85 Suppl 2:S530-541.
 18. Lehmborg K, Sprekels B, Nichols KE, et al. Malignancy-associated haemophagocytic lymphohistiocytosis in children and adolescents. *Br J Haematol*. 2015;May4[Epub ahead of print]
 19. Go RS, Wester SM. Immunophenotypic and molecular features, clinical outcomes, treatments, and prognostic factors associated with subcutaneous panniculitis-like T-cell lymphoma: a systematic analysis of 156 patients reported in the literature. *Cancer*. 2004;101(6):1404-1413.
 20. Willemze R, Jansen PM, Cerroni L, et al. Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases. *Blood*. 2008;111(2):838-845.
 21. Ferreri AJ, Dognini GP, Campo E, et al. Variations in clinical presentation, frequency of hemophagocytosis and clinical behavior of intravascular lymphoma diagnosed in different geographical regions. *Haematologica*. 2007;92(4):486-492.
 22. Hagihara M, Inoue M, Hua J, Iwaki Y. Lymphocyte-depleted Hodgkin lymphoma complicating hemophagocytic lymphohistiocytosis as an initial manifestation: a case report and review of the literature. *Intern Med*. 2012;51(21):3067-3072.
 23. Cho EY, Kim KH, Kim WS, Yoo KH, Koo HH, Ko YH. The spectrum of Epstein-Barr virus-associated lymphoproliferative disease in Korea: incidence of disease entities by age groups. *J Korean Med Sci*. 2008;23(2):185-192.
 24. Chang YH, Lu PJ, Lu MY, Wang JS, Tung CL, Shaw CF. Sequential transplants for respective relapse of Hodgkin disease and hemophagocytic lymphohistiocytosis: a treatment dilemma. *J Pediatr Hematol Oncol*. 2009;31(10):778-781.
 25. Shimazaki C, Inaba T, Nakagawa M. B-cell lymphoma-associated hemophagocytic syndrome. *Leuk Lymphoma*. 2000;38(1-2):121-130.
 26. Murase T, Nakamura S, Kawachi K, et al. An Asian variant of intravascular large B-cell lymphoma: clinical, pathological and cytogenetic approaches to diffuse large B-cell lymphoma associated with haemophagocytic syndrome. *Br J Haematol*. 2000;111(3):826-834.
 27. Hong M, Ko YH, Yoo KH, et al. EBV-Positive T/NK-Cell Lymphoproliferative Disease of Childhood. *Korean J Pathol*. 2013;47(2):137-147.
 28. Kimura H, Ito Y, Kawabe S, et al. EBV-associated T/NK-cell lymphoproliferative diseases in nonimmunocompromised hosts: prospective analysis of 108 cases. *Blood*. 2012;119(3):673-686.
 29. Stebbing J, Ngan S, Ibrahim H, et al. The successful treatment of haemophagocytic syndrome in patients with human immunodeficiency virus-associated multi-centric Castleman's disease. *Clin Exp Immunol*. 2008;154(3):399-405.
 30. Aronson IK, Worobec SM. Cytophagic histiocytic panniculitis and hemophagocytic lymphohistiocytosis: an overview. *Dermatol Ther*. 2010;23(4):389-402.
 31. Nichols CR, Roth BJ, Heerema N, Griep J, Tricot G. Hematologic neoplasia associated with primary mediastinal germ-cell tumors. *N Engl J Med*. 1990;322(20):1425-1429.
 32. Imashuku S. Etoposide-related secondary acute myeloid leukemia (t-AML) in hemophagocytic lymphohistiocytosis. *Pediatr Blood Cancer*. 2007;48(2):121-123.
 33. Lackner H, Urban C, Sovinz P, Benesch M, Moser A, Schwinger W. Hemophagocytic lymphohistiocytosis as severe adverse event of antineoplastic treatment in children. *Haematologica*. 2008;93(2):291-294.
 34. Teachey DT, Rheingold SR, Maude SL, et al. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. *Blood*. 2013;121(26):5154-5157.
 35. Machaczka M, Vaktas J, Klimkowska M, Hagglund H. Malignancy-associated hemophagocytic lymphohistiocytosis in adults: a retrospective population-based analysis from a single center. *Leuk Lymphoma*. 2011;52(4):613-619.
 36. Henter JI, Horne A, Arico M, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. *Pediatr Blood Cancer*. 2007;48(2): 124-131.
 37. Gupta A, Tyrrell P, Valani R, Benseler S, Weitzman S, Abdelhaleem M. The role of the initial bone marrow aspirate in the diagnosis of hemophagocytic lymphohistiocytosis. *Pediatr Blood Cancer*. 2008;51(3):402-404.
 38. Jordan MB, Allen CE, Weitzman S, Filipovich AH, McClain KL. How I treat hemophagocytic lymphohistiocytosis. *Blood*. 2011;118(15):4041-4052.
 39. Lehmborg K, McClain KL, Janka GE, Allen CE. Determination of an appropriate cut-off value for ferritin in the diagnosis of hemophagocytic lymphohistiocytosis. *Pediatr Blood Cancer*. 2014;61(11):2101-2103.
 40. Takahashi N, Chubachi A, Miura I, Nakamura S, Miura AB. [Lymphoma-associated hemophagocytic syndrome in Japan]. *Rinsho Ketsueki*. 1999;40(7):542-549.
 41. Fardet L, Galicier L, Lambotte O, et al. Development and Validation of the HScore, a Score for the Diagnosis of Reactive Hemophagocytic Syndrome. *Arthritis Rheumatol*. 2014;66(9):2613-2620.
 42. Lehmborg K, Ehl S. Diagnostic evaluation of patients with suspected haemophagocytic lymphohistiocytosis. *Br J Haematol*. 2012;160(3):275-287.
 43. Fardet L, Lambotte O, Meynard JL, et al. Reactive haemophagocytic syndrome in 58 HIV-1-infected patients: clinical features, underlying diseases and prognosis. *Aids*. 2010;24(9):1299-1306.
 44. Suga K, Kawakami Y, Hiyama A, et al. F-18 FDG PET/CT findings in a case of T-cell lymphoma-associated hemophagocytic syndrome with liver involvement. *Clin Nucl Med*. 2010;35(2):116-120.
 45. Horne A, Trottestam H, Arico M, et al. Frequency and spectrum of central nervous system involvement in 193 children with haemophagocytic lymphohistiocytosis. *Br J Haematol*. 2008;140(3):327-335.
 46. Deiva K, Mahlaoui N, Beaudonnet F, et al. CNS involvement at the onset of primary hemophagocytic lymphohistiocytosis. *Neurology*. 2012;78(15):1150-1156.
 47. Zhang K, Jordan MB, Marsh RA, et al. Hypomorphic mutations in PRF1, MUNC13-4, and STXBP2 are associated with adult-onset familial HLH. *Blood*. 2011;118(22):5794-5798.
 48. Bryceson YT, Pende D, Maul-Pavicic A, et al. A prospective evaluation of degranulation assays in the rapid diagnosis of familial hemophagocytic syndromes. *Blood*. 2012;119(12):2754-2763.
 49. Booth C, Gilmour KC, Veys P, et al. X-linked lymphoproliferative disease due to SAP/SH2D1A deficiency: a multicenter study on the manifestations, management and outcome of the disease. *Blood*. 2011;117(1):53-62.
 50. Marsh RA, Bleesing JJ, Filipovich AH. Flow cytometric measurement of SLAM-associated protein and X-linked inhibitor of apoptosis. *Methods Mol Biol*. 2013;979:189-197.
 51. Smyth MJ, Thia KY, Street SE, MacGregor D, Godfrey DI, Trapani JA. Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. *J Exp Med*. 2000;192(5):755-760.
 52. Chia J, Yeo KP, Whisstock JC, Dunstone MA, Trapani JA, Voskoboinik I. Temperature sensitivity of human perforin mutants unmasks subtotal loss of cytotoxicity, delayed FHL, and a predisposition to cancer. *Proc Natl Acad Sci USA*. 2009; 106(24):9809-9814.
 53. Clementi R, Locatelli F, Dupre L, et al. A proportion of patients with lymphoma may harbor mutations of the perforin gene. *Blood*. 2005;105(11):4424-4428.
 54. Zur Stadt U, Beutel K, Weber B, Kabisch H, Schneppenheim R, Janka G. A91V is a polymorphism in the perforin gene not causative of an FHLH phenotype. *Blood*. 2004;104

- (6):1909; author reply 1910.
55. Mehta PA, Davies SM, Kumar A, et al. Perforin polymorphism A91V and susceptibility to B-precursor childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. *Leukemia*. 2006;20(9):1539-1541.
 56. Santoro A, Cannella S, Trizzino A, Lo Nigro L, Corsello G, Arico M. A single amino acid change A91V in perforin: a novel, frequent predisposing factor to childhood acute lymphoblastic leukemia? *Haematologica*. 2005;90(5):697-698.
 57. Trapani JA, Thia KY, Andrews M, et al. Human perforin mutations and susceptibility to multiple primary cancers. *Oncoimmunology*. 2013;2(4):e24185.
 58. Machaczka M, Klimkowska M, Chiang SC, et al. Development of classical Hodgkin's lymphoma in an adult with biallelic STXBP2 mutations. *Haematologica*. 2013;98(5):760-764.
 59. Lorenzi L, Tabellini G, Vermi W, et al. Occurrence of nodular lymphocyte-predominant Hodgkin lymphoma in hermannsky-pudlak type 2 syndrome is associated to natural killer and natural killer T cell defects. *PLoS One*. 2013;8(11):e80131.
 60. Nagai K, Ochi F, Terui K, et al. Clinical characteristics and outcomes of chediak-Higashi syndrome: a nationwide survey of Japan. *Pediatr Blood Cancer*. 2013;60(10):1582-1586.
 61. Pagel J, Beutel K, Lehmborg K, et al. Distinct mutations in STXBP2 are associated with variable clinical presentations in patients with familial hemophagocytic lymphohistiocytosis type 5 (FHL5). *Blood*. 2012;119(25):6016-6024.
 62. Mahlaoui N, Ouachee-Chardin M, de Saint Basile G, et al. Immunotherapy of familial hemophagocytic lymphohistiocytosis with antithymocyte globulins: a single-center retrospective report of 38 patients. *Pediatrics*. 2007;120(3):e622-628.
 63. Marsh RA, Allen CE, McClain KL, et al. Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab. *Pediatr Blood Cancer*. 2013;60(1):101-109.
 64. Ravelli A, Grom AA, Behrens EM, Cron RQ. Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment. *Genes Immun*. 2012;13(4):289-298.
 65. Takahashi N, Chubachi A, Kume M, et al. A clinical analysis of 52 adult patients with hemophagocytic syndrome: the prognostic significance of the underlying diseases. *Int J Hematol*. 2001;74(2):209-213.
 66. Arca M, Fardet L, Galicier L, et al. Prognostic factors of early death in a cohort of 162 adult haemophagocytic syndrome: impact of triggering disease and early treatment with etoposide. *Br J Haematol*. 2015;168(1):63-8.
 67. Johnson TS, Terrell CE, Millen SH, Katz JD, Hildeman DA, Jordan MB. Etoposide selectively ablates activated T cells to control the immunoregulatory disorder hemophagocytic lymphohistiocytosis. *J Immunol*. 2014;192(1):84-91.
 68. Mizutani S, Kuroda J, Shimura Y, et al. Cyclosporine A for chemotherapy-resistant subcutaneous panniculitis-like T cell lymphoma with hemophagocytic syndrome. *Acta Haematol*. 2011;126(1):8-12.
 69. Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. *Lancet*. 2015;385(9967):517-28.
 70. Chellapandian D, Das R, Zelley K, et al. Treatment of Epstein Barr virus-induced haemophagocytic lymphohistiocytosis with rituximab-containing chemo-immunotherapeutic regimens. *Br J Haematol*. 2013;162(3):376-382.
 71. Parikh SA, Kapoor P, Letendre L, Kumar S, Wolanskyj AP. Prognostic factors and outcomes of adults with hemophagocytic lymphohistiocytosis. *Mayo Clin Proc*. 2014;89(4):484-492.
 72. Tong H, Ren Y, Liu H, et al. Clinical characteristics of T-cell lymphoma associated with hemophagocytic syndrome: comparison of T-cell lymphoma with and without hemophagocytic syndrome. *Leuk Lymphoma*. 2008;49(1):81-87.
 73. Lackner H, Seidel MG, Strenger V, et al. Hemophagocytic syndrome in children with acute monoblastic leukemia-another cause of fever of unknown origin. *Support Care Cancer*. 2013;21(12):3519-3523.